NovoCure Limited (NVCR) 追踪市盈率为负值 -8.8, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 4.6 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -11.30%, 前瞻盈利收益率 21.69%. PEG 0.05 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 51/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -5.1 | -0.34 | 4.72 | 8.10 | - |
| 2017 | -29.0 | 0.53 | 15.75 | 10.10 | - |
| 2018 | -48.4 | 33.86 | 27.39 | 12.39 | - |
| 2019 | -1,133.4 | 12.70 | 37.62 | 23.32 | - |
| 2020 | 881.7 | -2.39 | 36.65 | 35.33 | - |
| 2021 | -133.1 | 0.35 | 18.92 | 14.51 | - |
| 2022 | -83.0 | -1.45 | 17.40 | 14.27 | - |
| 2023 | -7.7 | -0.06 | 4.38 | 3.12 | - |
| 2024 | -19.1 | 0.95 | 8.92 | 5.31 | - |
| 2025 | -10.6 | 0.49 | 4.23 | 2.20 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-1.54 | $82.89M | $-131.85M | -159.1% |
| 2017 | $-0.70 | $177.03M | $-61.66M | -34.8% |
| 2018 | $-0.69 | $248.07M | $-63.56M | -25.6% |
| 2019 | $-0.07 | $351.32M | $-7.23M | -2.1% |
| 2020 | $0.18 | $494.37M | $19.81M | 4% |
| 2021 | $-0.56 | $535.03M | $-58.35M | -10.9% |
| 2022 | $-0.88 | $537.84M | $-92.53M | -17.2% |
| 2023 | $-1.95 | $509.34M | $-207.04M | -40.6% |
| 2024 | $-1.56 | $605.22M | $-168.63M | -27.9% |
| 2025 | $-1.22 | $655.35M | $-136.23M | -20.8% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-1.54 | $-1.91 – $-1.17 | $694.69M | $685.79M – $709.99M | 6 |
| 2027 | $-1.17 | $-1.49 – $-0.65 | $757.9M | $695.93M – $871.69M | 6 |
| 2028 | $-0.42 | $-0.50 – $-0.37 | $915.57M | $871.24M – $997.38M | 3 |
| 2029 | $2.45 | $2.30 – $2.73 | $1.52B | $1.45B – $1.66B | 1 |
| 2030 | $4.79 | $4.49 – $5.35 | $1.84B | $1.75B – $2B | 1 |
